Delayed eosinophil apoptosis in asthma

Journal of Allergy and Clinical Immunology

Volumn 106, Issue 1 I, 2000, Pages 77-83

  Kankaanranta, Hannu ^b,c   Lindsay, Mark A ^a   Giembycz, Mark A ^a   Zhang, Xianzhi ^b   Moilanen, Eeva ^b,c   Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Albuterol; Apoptosis; Asthma; Eosinophil; Fenoterol; GM CSF; IL 5; Salmeterol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FENOTEROL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; INTERLEUKIN 5; PROPIDIUM IODIDE; SALBUTAMOL; SALMETEROL; STEROID;

ADULT; APOPTOSIS; ARTICLE; ASTHMA; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; EOSINOPHILIA; FEMALE; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL;

EID: 0033941414     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2000.107038     Document Type: Article

References (28)

1. Haslett C. Granulocyte apoptosis and inflammatory disease. Br Med Bull 1997;53:669-83.
2. Walsh GM. Mechanisms of human eosinophil survival and apoptosis. Clin Exp Allergy 1997;27:482-7.
3. Simon HU, Yousefi S, Schranz C, Schapowal A, Bachert C, Blaser K. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol 1997;158:3902-8.
4. Murphy S, Bleecker ER, Boushey H, Buist AS, Busse W, Clark NM, et al. Expert Panel Report 2: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health; 1997. NIH publication No.: 97-4051:. Also available at http:/www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.
5. Hansel TT, Pound JD, Pilling D, Kitas GD, Salmon M, Gentle TA, et al. Purification of human blood eosinophils by negative selection using immunomagnetic beads. J Immunol Methods 1989;122:97-103.
6. Kankaanranta H, De Souza PM, Barnes PJ, Salmon M, Giembycz MA, Lindsay, MA. SB 203580, an inhibitor of p38 mitogen-activated protein kinase, enhances constitutive apoptosis of cytokine-deprived human eosinophils. J Pharm Exp Ther 1999;290:621-8.
7. Kankaanranta H, De Souza PM, Giembycz MA, Lindsay MA. Human eosinophil isolation and the measurement of apoptosis. In: Chung KF, Adcock IM, editors. Methods in molecular medicine: asthma. Totowa: Humana Press. In press.
8. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
9. Woolley KL, Gibson PG, Carty K, Wilson AJ, Twaddell SH, Woolley MJ. Eosinophil apoptosis and the resolution of airway inflammation in asthma. Am J Respir Crit Care Med 1996;154:237-43.
10. Wedi B, Raap U, Lewrick H, Kapp A. Delayed eosinophil programmed cell death in vitro: a common feature of inhalant allergy and extrinsic and intrinsic atopic dermatitis. J Allergy Clin Immunol 1997;100:536-43.
11. Tai PC, Sun L, Spry CJ. Effects of IL-5, granulocyte/macrophage colony-stimulating factor (GM-CSF) and IL-3 on the survival of human blood eosinophils in vitro. Clin Exp Immunol 1991;85:312-6.
12. Yamaguchi Y, Suda T, Ohta S, Tominaga K, Miura Y, Kasahara T. Analysis of the survival of mature human eosinophils: interleukin-5 prevents apoptosis in mature human eosinophils. Blood 1991;78:2542-7.
13. Stern M, Meagher L, Savill J, Haslett C. Apoptosis in human eosinophils: programmed cell death in the eosinophil leads to phagocytosis by macrophages and is modulated by IL-5. J Immunol 1992;148:3543-9.
14. 2 and dibutyryl cyclic adenosine monophosphate prolong eosinophil survival in vitro. J Allergy Clin Immunol 1999;104:153-62.
15. Hallsworth MP, Giembycz MA, Barnes PJ, Lee TH. Cyclic AMP-elevating agents prolong or inhibit eosinophil survival depending on prior exposure to GM-CSF. Br J Pharmacol 1996;117:79-86.
16. Giembycz MA, Lindsay MA. Pharmacology of the eosinophil. Pharmacol Rev 1999;51:213-340.
17. Evans DJ, Lindsay MA, O'Connor BJ, Barnes PJ. Priming of circulating human eosinophils following late response to allergen challenge. Eur Respir J 1996;9:703-8.
18. Druilhe A, Wallaert B, Tsicopoulos A, Lupe e Silva JR, Tillie-Leblond I, Tonnel AB, et al. Apoptosis, proliferation, and expression of Bcl-2, Fas, and Fas ligand in bronchial biopsies from asthmatics. Am J Respir Cell Mol Biol 1998;19:747-57.
19. Vignola AM, Chanez P, Chiappara G, Siena L, Merendino A, Reina C, et al. Evaluation of apoptosis of eosinophils, macrophages, and T lymphocytes in mucosal biopsy specimens of patients with asthma and chronic bronchitis. J Allergy Clin Immunol 1999;103:563-73.
20. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockroft D, et al. The use of β-agonists and the risk of death or near death from asthma. N Engl J Med 1992;326:501-6.
21. Gauvreau GM, Jordana M, Watson RM, Cockroft DW, O'Byrne PM. Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. Am J Respir Crit Care Med 1997;156:1738-45.
22. Nielson CP, Hadjokas NE. Beta-adrenoceptor agonists block corticosteroid inhibition in eosinophils. Am J Respir Crit Care Med 1998;157:184-91.
23. Jonkman JHG, Freie HMP, van der Boon WJV, Grasmeijer G. Single dose absorption profiles and bioavailability of two different salbutamol tablets. Arzneimittel Forschung 1986;36:1133-5.
24. Powell ML, Chung M, Weisberger M, Gural R, Radwanski E, Symchowicz S, et al. Multiple-dose albuterol kinetics. J Clin Pharmacol 1986; 26:643-6.
25. Hochhaus G, Möllmann H. Pharmacokinetic/pharmacodynamic characteristics of the β-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol 1992;30:342-62.
26. Adkins JC, McTavish D. Salmeterol: a review of its pharmacological properties and clinical efficacy in the management of children with asthma. Drugs 1997;54:331-54.
27. Schleimer RP, Bochner BS. The effects of glucocorticoids on human eosinophils. J Allergy Clin Immunol 1994;94:1202-13.
28. Spry CJF. The natural history of eosinophils. In: Smith H, Cook RM, editors. Immunopharmacology of eosinophils. London: Academic Press; 1993. p 1-9.